SPOTLIGHT -
May 9th 2024
The collaboration is a part of a broader strategy to combat cardiometabolic and rare diseases.
Strategic financing from Oaktree Capital Management and OMERS Life Sciences is expected to support the US launch of ensifentrine, Verona’s promising chronic obstructive pulmonary disease treatment.
May 7th 2024
Joint venture aims to develop up to 10 new cell and gene therapy products targeting areas with high unmet medical needs.
May 3rd 2024
Deal includes a number of radioligand therapies targeting solid tumors, such as breast, prostate, and lung cancers.
May 2nd 2024
A Harvard Business School Healthcare Alumni Association Q&A with Matt Wolf, president of Biopharma Services at Cencora.
Are We Close to a Peak in Interest Rates?
When you know it is coming—but it takes forever to get there.
No Rate Relief in Sight for Biotech
Strong economic data in other sectors mean rising ‘real’ rates.
More Evidence is Pointing to Potential Swing for Biotech
Could the sector be nearing a turning point in performance?
Jami Rubin Announced as Boundless Bio Chief Financial Officer
New executive brings over 30 years of experience in the biopharma industry.
Shifting Macro Trends Offer Hope for Biotech Performance Boost
But will Washington’s dealmaking stance upend the momentum?
‘Bolus’ Markets: Unique Business Opportunities with Promise and Risk
Conditions require a disciplined approach to drug pricing.
The Quest to Fully Address Prescription Drug Affordability
The Medicare Part D cap won’t solve need for financial assistance.
Could a Rates Pivot By Fed Change Biotech’s Fate?
Such a scenario is one possibility as the bear market languishes on.
When to Utilize Commercial Outsourcing
When deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.
Will Recent Surge in M&A Dealmaking Save Biotech Sector?
The ‘blistering’ pace may further divide the haves from the have-nots.
Does the Biotech Sector Have Reason to Be Optimistic?
Over two years into a bear market, it still can’t catch a sustainable bid.
Biotech Challenges & Financing
Experts from Kallyope share biotech challenges they have faced and overcome as well as ways to go about securing funds in this exclusive Q&A.
Value Creation Through Portfolio-Based Corporate Strategy
Looking at corporate value through a portfolio lens provides an astute and reliable path to genuine value creation.
Biopharma M&A: Year in Review, Ripples Ahead
While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.
More than Ever, Data Will Dictate Future Fortunes
Is stock market outperformance for biotech still in the cards for 2023?
An Inside Look at Pharma Revenue Management
According to the 2023 State of Revenue Report, pharma companies are prioritizing digital transformation while struggling with inflation and supply chain disruptions.
Data Signals Some Green Shoots for Biotech in 2023
Chronicling the market’s rise and fall—and signs of potential recovery.
Biopharma Investment Implications: Looking Back and Forward
What a changing economy and related trends could mean for 2023.
Back in Person, Sparks Could Fly at Upcoming J.P. Morgan Conference
Will biopharma investment heat up and signal better fortunes for 2023?
The New Reality for Industry Dealmaking May be Setting In
Focus is on cash: who’s got it, who doesn’t, and what will it mean?
Discerning Dealmaking: Caution Flag Still Raised in Biopharma M&A Race
Big pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.
All About the Rates: The Fallout of Fed Hikes for Biotech
As fundamentals improve, potential rate plateau could ignite growth.
Q&A With Greg Rotz, PLS Advisory Leader at PwC
Rotz discusses a report he co-authored for PwC about how life sciences companies perform on the S&P 500.
21st Annual Industry Audit: Pharma Performance Check
Our latest metrics tally across seven business-key measures uncovers some familiar players pacing the field in delivering shareholder value and getting the most from their investments.
The Biotech Rally Continues—What’s Fueling the Surge?
Biotech stocks and the indexes have staged an impressive recovery.
Q&A With Kim Barnes, Executive Vice President at Phacilitate
Barnes discusses alternative reimbursement plans for expensive, one-off therapies.
Navigating the Financial Meltdown for Biopharma
A review of pharma and biotech equity market, IPO, and M&A trends and outputs through the first half of 2022—and implications for the future as disruptions continue to have an impact.
Has Biotech Bottomed Out—and is Recent Recovery Sustainable?
A look at the driving factors behind renewed optimism.
Positive Outlook for Post-Pandemic Biotech
A recent analysis of the biotech market shows promising signs.
Q&A With Bryan Kobel, CEO, TC BioPharm
Kobel discusses taking a company public during a challenging time in the market.